Document:

<PAGE>

                                                                   EXHIBIT 10.14

THIRD AMENDMENT OF LEASE

THIS THIRD AMENDMENT OF LEASE ("Amendment") is made and entered into effective
as of August 1, 2005 by and between CSM INVESTORS, INC., a Minnesota corporation
("Landlord") and SYNOVIS LIFE TECHNOLOGIES, INC., a Minnesota corporation
("Tenant").

                                    RECITALS

A.   Landlord and Tenant are parties to a Lease dated February 28, 1995, as
     amended by that certain First Amendment of Lease dated September 23, 2002
     ("First Amendment"), and as amended by that certain Second Amendment of
     Lease dated January 1, 2004 ("Second Amendment") (collectively, the
     "Lease"), pursuant to which Tenant leases from Landlord the Premises,
     consisting of approximately 65,002 square feet within the WESTGATE BUSINESS
     CENTER PHASE IV located at 2575 UNIVERSITY AVENUE WEST, SUITE 180, ST.
     PAUL, MINNESOTA, as more particularly described in the Lease.

B.   Tenant and Landlord agreed to expand the area of the Premises and extend
     the term of the Lease pursuant to the terms of the First Amendment and the
     Second Amendment.

C.   The parties wish to amend certain terms and conditions of the Lease as more
     particularly set forth herein.

NOW, THEREFORE, in consideration of the foregoing recitals, the mutual covenants
herein contained, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, Landlord and Tenant agree that the
Lease is hereby amended as follows:

                                    AGREEMENT

1.   SECTION 1.6.  BASE RENT:

     A.   ORIGINAL PREMISES: Pursuant to Section 9 of the First Amendment,
          commencing August 1, 2005, the market Base Rent for the original
          Premises (comprising 36,027 rentable square feet) is as follows:

          PERIOD                 MONTHLY BASE RENT          PER RENTABLE SQ. FT.
          ------                 -----------------          --------------------

          8/1/05-12/31/08           $29,853.23                      $9.94

          OPTION TERM:

          PERIOD                 MONTHLY BASE RENT          PER RENTABLE SQ. FT.
          ------                 -----------------          --------------------

          1/1/09-12/31/11           Market                          Market

     B.   SECOND EXPANSION AREA:  The Base Rent for the Second Expansion Area
          (comprising 28,975 rentable square feet) is as follows:

<PAGE>

          PERIOD                 MONTHLY BASE RENT          PER RENTABLE SQ. FT.
          ------                 -----------------          --------------------

          8/1/05-12/31/06           $26,507.30                     $10.978
          1/1/07-12/31/08           $27,651.81                     $11.452

          OPTION TERM:

          PERIOD                 MONTHLY BASE RENT          PER RENTABLE SQ. FT.
          ------                 -----------------          --------------------

          1/1/09-12/31/11           Market                         Market

2.   BROKERAGE. Landlord and Tenant each represents and warrants to the other
     that there is no obligation to pay any brokerage fee, commission, finder's
     fee or other similar charge in connection with this Amendment. Each party
     covenants that it will defend, indemnify and hold harmless the other party
     from and against any loss or liability by reason of brokerage or similar
     services alleged to have been rendered to, at the instance of, or agreed
     upon by said indemnifying party. Notwithstanding anything herein to the
     contrary, Landlord and Tenant agree that there shall be no brokerage fee or
     commission due on expansions, options or renewals by Tenant.

3.   MISCELLANEOUS. Except as otherwise provided herein, all capitalized terms
     used herein shall have the meaning ascribed to them in the Lease. Except as
     specifically modified herein, all of the covenants, conditions, and
     obligations under the Lease shall remain unchanged and in full force and
     effect. In the event of a conflict between the terms of the Lease and this
     Amendment, the terms of this Amendment shall prevail. This Amendment shall
     be binding upon the parties hereto and their respective successors and
     assigns. This Amendment may be executed in one or more counterparts each of
     which when so executed and delivered shall constitute an original, but
     together said counterparts shall constitute one and the same instrument.
     Execution copies of this Amendment may be delivered by facsimile, and the
     parties hereto agree to accept and be bound by facsimile signatures hereto.

IN WITNESS WHEREOF, the parties have executed this Amendment as of the day and
year first above written.

LANDLORD:                                   TENANT:
--------                                    ------

CSM INVESTORS, INC.                          SYNOVIS LIFE TECHNOLOGIES, INC.

By:      /s/ David Carland              By:     /s/ Brett Reynolds
   --------------------------------         ------------------------------------
Print Name:       David Carland         Print Name:       Brett Reynolds
           ------------------------                 ----------------------------
Print Title:Sr. Vice President          Print Title:  VP Finance and CFO
                              -----                   --------------------------

244783 - LEASING/PROPERYMGMT - SYNOVIS THIRD AMENDMENT FOR WESTGATE IV - Leas

                                       2<PAGE>

                                                                   EXHIBIT 10.19

NON-EMPLOYEE DIRECTORS' COMPENSATION

In fiscal 2006, non-employee directors will receive compensation of $1,000 per
month for Board membership and $1,000 for each Board meeting attended and will
be reimbursed for out of pocket expenses in connection with attending a Board
meeting. Committee members will receive additional compensation of $750 for each
Audit and/or Compensation Committee meeting attended, with no additional
compensation paid for service on the Nominating and Governance Committee. The
chairman of the Board will receive an annual stipend of $4,000 per year, and the
chairs of the Audit and Compensation Committees will each receive an annual
stipend of $2,000.

Directors who are otherwise employees of the Company do not receive any
additional compensation for their service on the Board or any of its committees.<PAGE>

                                                                   EXHIBIT 10.21

September 30, 2005

Name
Address

Dear Sir/Madam,

As has been previously discussed with you and approved by the board of directors
of Synovis Life Technologies, Inc. (the "Company"), that portion of your options
granted on December 1, 2004 to purchase 9,000 shares of Company common stock,
which would otherwise have vested on December 1, 2007, will be terminated,
without further consideration to you, effective September 30, 2005

The balance of your options granted on December 1, 2004 to purchase 18,000
shares of the Company stock, 9,000 of which vest on December 1, 2005 and 9,000
of which vest on December 1, 2006, are not effected by this action.

Please sign this letter below to document your consent to the termination of
these options.

Should you have further questions, feel free to contact me.

Sincerely,

Brett Reynolds
VP of Finance and Chief Financial Officer
Synovis Life Technologies, Inc.

I hereby consent to the termination of options to purchase 9,000 shares of
Synovis Life Techonologies, Inc. common stock that were granted to me on
December 1, 2004 and were scheduled to vest on December 1, 2007.

Signature: ________________________________________
           Name

Date: ____________________<PAGE>

                                                                   EXHIBIT 10.22

           SUMMARY OF FISCAL 2006 NAMED EXECUTIVE OFFICER COMPENSATION

Set forth is a summary of fiscal 2006 compensation arrangements between Synovis
Life Technologies, Inc. (the "Company") and certain of its executive officers
who are expected to constitute the Company's "named executive officers" (defined
in Regulation S-K Item 402(a)(3)) for the year. All of the Company's executive
officers are at-will employees whose compensation and employment status may be
changed at any time in the discretion of the Company's Board of Directors,
subject only to the terms of the Management Change in Control Agreements between
the Company and these executive officers (the forms of which have been filed or
incorporated by reference as exhibits to the Company's annual report on Form
10-K).

BASE SALARY

Effective November 1, 2005, the named executive officers are scheduled to
receive the following annual base salaries in their current positions:

<TABLE>
<CAPTION>
Name and Current Position                                                          Base Salary
-------------------------                                                          -----------
<S>                                                                                <C>
Karen Gilles Larson                                                                $   375,000
(President and Chief Executive Officer)

David A. Buche                                                                     $   187,000
(Vice President and Chief Operating Officer of
Synovis Surgical Innovations)

Mary L. Frick                                                                      $   170,000
(Vice President of Regulatory Affairs, Clinical Affairs and Quality)

Richard W. Kramp                                                                   $   225,000
(President and Chief Operating Officer of
Synovis Interventional Solutions)

B. Nicholas Oray, Ph.D.                                                            $   171,500
(Vice President of Research and Development)
</TABLE>

ANNUAL CASH INCENTIVE COMPENSATION

For fiscal 2006, the Company's executive officers are eligible to receive annual
cash incentive compensation up to 5% of their base salary based upon a
subjective evaluation by the Company's Compensation Committee of the Board of
Directors of the individual executive officer's performance and achievement of
specific individual objectives during the period. In fiscal 2006, the
Compensation Committee also established an incentive cash compensation program
based upon achievement of aggressive Company financial performance goals.
Additional cash incentive compensation may be awarded at the discretion of the
Compensation Committee for performance or achievement above individual goals.

<PAGE>

STOCK OPTIONS

On September 30, 2005, immediately vested options to purchase shares of common
stock listed below, at an exercise price of $10.75 per share (the closing price
of a share of common stock on the date of the grant), were awarded to each named
executive officer under the Company's 1995 Stock Incentive Plan:

<TABLE>
<CAPTION>
Name                                     Options Granted
----                                     ---------------
<S>                                      <C>
Karen Gilles Larson                          15,000
David A. Buche                               12,000
Mary L. Frick                                10,000
Richard W. Kramp                             12,000
B. Nicholas Oray, Ph.D.                      10,000
</TABLE>

BENEFITS

The Company provides medical, dental and life and disability insurance benefits
as well as a 401(k) retirement plan and a stock purchase plan to its executive
officers. The same benefits are available to all Company employees.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]